The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
Yang Y, Zhang G, Hu C, Luo W, Jiang H, Liu S, Yang H.
BMC Urol. 2022 Nov 30;22(1):196. doi: 10.1186/s12894-022-01141-1.
PMID:36451132
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J.
Ann Oncol. 2024 Jan;35(1):91-97. doi: 10.1016/j.annonc.2023.09.3114. Epub 2023 Oct 21.
PMID:37871703
[Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].